PD2.06 EGFR Inhibitors + Bevacizumab Demonstrated Superior Efficacy Compared with EGFR Inhibitors Alone as First-line Treatment in Advanced NSCLC Patients with EGFR Mutations and BIM Deletion Polymorphisms

Authors :: J. Ávila
Luis Mas
Feliciano Barrón
L. Corrales-Rodriguez
Helano C. Freitas
C. Martin
Rosa Rosell
C. Sotelo
Pilar Archila
L. Zatarain Barron
Andrés Felipe Cardona
Alejandro Ruiz-Patiño
Carlos Vargas
V. Cordeiro De Lima
Hernán Carranza
Oscar Arrieta
D. Mayorga
July Rodriguez
Jorge Otero
Luisa Ricaurte
Source :: Journal of Thoracic Oncology. 14:S1172-S1173
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Pulmonary and Respiratory Medicine
First line treatment
Oncology
Bevacizumab
Egfr mutation
business.industry
medicine
Cancer research
business
medicine.drug
EGFR inhibitors

Tools